Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
2018 · Annals of Oncology · 756 citations
https://doi.org/10.1093/annonc/mdy517
H
H. S. Rugo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
140
Papers
2.5K
Citations
21
h-index
36
i10-index
H. S. Rugo is an academic researcher from City Of Hope National Medical Center. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research. The author has an h-index of 21, co-authored 119 publications.
Papers by this author
worksPerformance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
2019 · Annals of Oncology · 113 citations
https://doi.org/10.1093/annonc/mdz394.009
ICON 2013: Practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer
2014 · Indian Journal of Cancer · 14 citations
https://doi.org/10.4103/0019-509x.134650
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis
2025 · ESMO Open · 2 citations
https://doi.org/10.1016/j.esmoop.2025.105304
LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
2024 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2024.08.2253
LBA2 Rates of pathologic complete response after VV1 and cemiplimab (alone and in treatment sequence-strategy) in the neoadjuvant setting: Results from the I-SPY 2.2 trial
2025 · ESMO Open · 0 citations
https://doi.org/10.1016/j.esmoop.2025.105113
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat